Compare HSBC Holdings plc (HSBC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Organon & Co. Common Stock — how do they compare? HSBC Holdings plc trades at $94.89 (market cap $322.45B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: HSBC Holdings plc is far larger — about 89.3× Organon & Co. Common Stock's market cap, and HSBC Holdings plc pays the higher dividend (3.99%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Organon & Co. Common Stock for 0 Days on average.
| HSBC | OGN | |
|---|---|---|
Market Cap | $322.45B | $3.61B |
Volume | 2,058,215 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $107.86 | $13.81 |
52-Week Low | $65.67 | $5.70 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $11.03B |
Dividend Yield | 3.99% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with mixed technical signals showing bearish momentum but neutral oscillators. The bank demonstrates strong profitability with a 34.54% net income margin and reasonable valuation at 13.42 P/E. Recent strategic moves include expanding US wealth services and re-entering India's equity broking market, while analyst sentiment remains divided with 38% buy ratings.
HSBC presents a balanced opportunity with solid fundamentals and global expansion initiatives, though technical weakness and CFO transition risks warrant caution. The stock's current valuation appears reasonable relative to earnings power, but investors should monitor execution of growth strategies amid competitive banking landscape and potential macroeconomic headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
